BioEclipse Therapeutics™ is a clinical-stage oncology company with a uniquely differentiated platform comprising immune cells expanded to billions of cells (specifically, cytokine induced killer (CIK) immune cells) combined with a powerful oncolytic virus payload (vaccinia).
BioEclipse holds the exclusive IP to commercialize the powerfully synergistic effect of combining these components into a single, multi-mechanistic therapy that has demonstrated (in preclinical studies) that it can defeat cancer and prevent relapse and recurrence in multiple tumor types, including difficult to treat solid tumors and metastatic disease.
In Q2 2020, the US FDA cleared BioEclipse to commence our Phase 1 study with CRX100. An open Phase I clinical trial will begin in the US this fall for patients with resistant and recurring solid tumors. We are truly excited about our Phase 1 trial design and the quality of data that will arise from the first 24 patients.
BioEclipse holds the exclusive IP to commercialize the powerfully synergistic effect of combining these components into a single, multi-mechanistic therapy that has demonstrated (in preclinical studies) that it can defeat cancer and prevent relapse and recurrence in multiple tumor types, including difficult to treat solid tumors and metastatic disease.
In Q2 2020, the US FDA cleared BioEclipse to commence our Phase 1 study with CRX100. An open Phase I clinical trial will begin in the US this fall for patients with resistant and recurring solid tumors. We are truly excited about our Phase 1 trial design and the quality of data that will arise from the first 24 patients.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Oncology
Lead Product in Development:
CRX100
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
